Press Releases


Neuro-Ophthalmologist, Reconstructive and Aesthetic Oculoplastic Surgeon Dr. Steven Gross joins the Kaufman Eye Institute

The Kaufman Eye Institute with offices in Zephyrhills, Sun City Center, Wesley Chapel and Bushnell is pleased to announce that board certified ophthalmologist and neurologist, Steven Gross,M.D. has joined KEI. Dr Gross sees patients in all of the Kaufman Eye Institute's locations.

"We are pleased to welcome such a talented physician as Dr Gross to our Institute" says Dr Kaufman the Medical Director of the Kaufman Eye Institute. "Not only is Dr Gross board certified in ophthalmology and neurology, he is fellowship trained in reconstructive and aesthetic oculoplastic surgery, neuro ophthalmology, and pediatric ophthalmology."

Originally from Queens New York, a graduate of Northwestern University with a Bachelor of Science Degree, Dr Gross went on to earn his Doctorate of Medicine from the University of Illinois in Chicago. He completed residencies in Ophthalmology at the Manhattan Eye and Ear Hospital, in Neurology at Columbia University, and in Pediatrics at the University of Illinois and at Washington University in St Louis. In addition, Dr Gross completed ophthalmology fellowships in neuro ophthalmology at the Harkness Eye Institute of Columbia University, reconstructive and aesthetic oculoplastic surgery at the Southeastern Oculoplastic Center in Atlanta, and in pediatric ophthalmology and strabismology at the Baylor College of Medicine and the Cullen Eye Institute in Houston.

Dr Gross's services include cosmetic and functional eyelid lifts and tucks, blepharoplasty,entropion, ectropion, DCRs, browlifts, Botox, fillers, adult strabismus and neuro ophthalmologic evaluations.

Dr Gross is ranked as one of America's Top Ophthalmologists and listed as one of the Best Doctors in America. He is an Assistant Clinical Professor of Ophthalmology at the University of South Florida College of Medicine.



Stuart Kaufman, M.D. selected as Bausch & Lomb’s Trulign™ Toric Lens implant surgeon.

Stuart J. Kaufman, M.D., Cataract Surgeon with offices in Zephyrhills, Sun City Center, Bushnell and Wesley Chapel has been selected as a Trulign™ implant cataract surgeon in the initial roll out of Bausch & Lomb’s new Trulign™ Toric Lens, the only intraocular lens which can reduce astigmatism and also provide distance, intermediate and near vision, all without glasses.

The Bausch & Lomb Trulign™ Toric Lens IOL represents a significant breakthrough in multifocal accommodative lens implant technology, more commonly referred to as “Lifestyle Lenses”. It is suited for astigmatic cataract patients who take part in a variety of activities and require a full range of of vision without glasses. Most patients to have the FDA Approved Trulign™ Toric Lens implants after cataract surgery experience the ability to work on a computer, drive, go shopping, participate in sports activities, do handy work, swim, walk and watch television all without eyeglasses.

The contact Dr. Kaufman, call the Kaufman Eye Institute at 1-855-SEE BEST.


Best Eye Surgeon in the South Shore8/24/2011:

Best Eye Surgeon in the South Shore area.

Kaufman Eye Institute is gratified at being selected as the Best Eye Surgeon in the South Shore area. We have always strived to provide the absolute highest quality eye care for our patients. It is major accomplishment to know how patients feel about our practice and that they have taken the time to respond.



CATT first year results are in!

The Comparison of AMD Treatments Trial (CATT) is a head to head study of Avastin (bevacizumab) vs Lucentis (ranibizumab) funded by the National Eye Institute.  The highly anticipated first year results of the two year study have been released.

Take home points:

  • At 1 year, Avastin and Lucentis had equivalent effects on visual acuity when administered according to the same schedule.
  • Lucentis given as needed with monthly evaluation had effects on vision that were equivalent to those of Lucentis administered monthly.
  • Differences in rates of serious adverse events require further study.

Philip J. Rosenfed, MD, Ph.D., the physician who pioneered the use of bevacizumab in AMD patients, comments:

"The CATT results, together with the totality of global experience, support the use of either bevacizumab (Avastin) or ranibizumab (Lucentis) for the treatment of neovascular AMD. An as needed regimen is an acceptable alternative to a monthly regimen, but strict compliance on the part of both the clinician and the patient is required. Health care providers and payers worldwide will now have to justify the cost of using ranibizumab (Lucentis). Regulators in certain countries will be forced to reconsider their policies that make it illegal to use drugs off-label, particularly when so many of their citizens cannot afford ranibizumab (Lucentis). The CATT data support the continued global use of intravitreal bevacizumab (Avastin) as an effective, low-cost alternative to ranibizumab (Lucentis)."

Read the full article from the New England Journal of Medicine

My take:

"The CATT study reaffirms that both drugs are very good. If a patient is doing well on one there is little reason to change to another.  These results support an individualized approach to treatment. We look forward to the final result of this pivotal study in the next year."

Selina J. Lin, MD


Know Your Risk of Progression of Macular Degeneration with Macula Risk®

Dr. Selina Lin, a Board Certified, fellowship trained Retina and Macular Specialist introduces to our practice a DNA test called Macula Risk®. This test is used to identify genetic markers associated with macular degeneration progression. Learn your risk of macular degeneration.

Click here to learn more about Macula Risk®


Timothy Parker, O.D. Joins the Kaufman Eye Institute.

The Kaufman Eye Institute welcomes Timothy Parker, O.D. to our staff. Dr. Parker is a Florida Board Certified Optometrist.

Click here to learn more about Dr. Parker



Selina Lin, M.D. Joins the Kaufman Eye Institute.

The Kaufman Eye Institute welcomes Selina Lin, M.D. to our staff. Dr. Lin is a Board Certified, fellowship trained Retina and Macular Specialist.

Click here to learn more about Dr. Lin



Stuart J. Kaufman M.D. was interviewed in Ophthalmology Times in an article entitled “Eyelid cleanser can reduce bacterial colonization.” Published in Ophthalmology Times - June 23, 2008

In this article, Dr. Kaufman discusses his experience and recommendations with SteriLid the only bactericidal cleaner for the treatment of blepharitis.

Click here to download the article


Roger Gstalder, M.D. joins the Kaufman Eye Institute.

The Kaufman Eye Institute welcomes Roger Gstalder, M.D. to our staff. Dr. Gstalder is a Full Professor of Ophthalmology at the University of South Florida College of Medicine. He is Board Certified and specializes in Eyelid Surgery, Pediatrics, and Refractive Surgery.

Click here to learn more about Dr. Gstalder


The Kaufman Eye Institute was named a Crystalens® Center of Excellence by Bausch and Lomb.

The Kaufman Eye Institute is one of the first Crystalens® practices in Central Florida that has been awarded the high honor of being named a Crystalens® Center of Excellence. The Kaufman Eye Institute is one of about 100 practices in the United States noted for their experience and long term excellent outcomes.


Stuart J. Kaufman, M.D. implants the first Crystalens™ in Central Florida and the Tampa Bay Area.

Stuart J. Kaufman, M.D. is the first surgeon in Central Florida and the Tampa Bay Area to implant the Crystalens®. The Crystalens® is the only FDA approved accommodating lens implant which can correct distance, near, and intermediate vision. Most patients who have their cataracts removed and the Crystalens® implanted do not need any glasses after their cataract surgery. The revolutionary design element that makes the Crystalens® the state-of-the-art replacement lens are the hinges which are designed to allow the lens to move or accommodate and focus on objects near, far, and all distances in between seamlessly.

Click here to learn more about Crystalens®